Genetic obesity

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Sep 2026Inherited and Environmental Risks Acting on Body Weight

University of Washington — NA

TrialNOT YET RECRUITING
Jun 2026Study of Genetics in Childhood Obesity

Georgina Yan

TrialNOT YET RECRUITING
Apr 2026A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity

National Institute of Environmental Health Sciences (NIEHS)

TrialNOT YET RECRUITING
Jan 2026Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study

Augusta University — NA

TrialENROLLING BY INVITATION
Nov 2025International Genetic Obesity Registry

University of Ulm

TrialRECRUITING
Oct 2025Better4All Personalized Intervention

Harokopio University — NA

TrialNOT YET RECRUITING
Sep 2025The Resistant Starch Intervention for Cognitive Enhancement

Second Affiliated Hospital, School of Medicine, Zhejiang University — NA

TrialNOT YET RECRUITING
Jun 2025Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Second Affiliated Hospital, School of Medicine, Zhejiang University — NA

TrialRECRUITING
Jun 2025Better4All Personalized Intervention Pilot Study

Harokopio University — NA

TrialRECRUITING
May 2025The Causal Role of Ketone Bodies in Obesity-associated Disease Prevention - Combining Genetic Epidemiology With a Randomised Trial to Infer Causality

University of Bath — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Genetic obesity.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

WEGOVY

(SEMAGLUTIDE)standard

Novo Nordisk

GLP-1 Receptor Agonist [EPC]

12.1 Mechanism of Action Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

18 active trials
1Phase 3
1Phase 4
5N/A
11Unknown
18Total recruiting
Search clinical trials for Genetic obesity

Recent News & Research

1 article
BREAKINGFDAMar 19, 2026

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide

The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection for weight loss and long-term maintenance of weight loss for certain adult patients.

Read ↗

Browse all Genetic obesity news →

Specialist Network

Top 6 by expertise

View all Genetic obesity specialists →

Quick Actions